Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7986397 | 0.84 | ALDH1A1 (0.54) | ALDH1A1GAATSHR | |
| SCHEMBL4518149 | 0.75 | MAPK1 (0.56) | HRH3ALDH1A1SLC1A2POLBLMNA | |
| SCHEMBL10969069 | 0.74 | ALDH1A1 (0.59) | HRH3ALDH1A1SLC1A2POLBLMNA | |
| SCHEMBL4408776 | 0.72 | ALDH1A1 (0.60) | HRH3ALDH1A1SLC1A2POLBLMNA | |
| SCHEMBL1414194 | 0.71 | ALDH1A1 (0.53) | ALDH1A1LMNATSHRMAPK1 | |
| SCHEMBL1318724 | 0.67 | LMNA (0.57) | ALDH1A1LMNATSHRMAPK1 | |
| SCHEMBL27333607 | 0.67 | LMNA (0.57) | ALDH1A1GAALMNATSHRMAPK1 | |
| SCHEMBL18387989 | 0.67 | ALDH1A1 (0.57) | HRH3ALDH1A1SLC1A2POLBLMNA | |
| SCHEMBL717194 | 0.67 | CYP19A1 (0.43) | ALDH1A1 | |
| SCHEMBL6357644 | 0.66 | ALDH1A1 (0.46) | HRH3ALDH1A1POLBLMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306397-A1 | Method for the production of substituted azoles | LANXESS DEUTSCHLAND GMBH (DE) | 2009-12-10 | — | — | US | disclosed |
| EP-1891025-A1 | METHOD FOR THE PRODUCTION OF SUBSTITUTED AZOLES | Lanxess Deutschland GmbH (DE) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006131228-A1 | METHOD FOR THE PRODUCTION OF SUBSTITUTED AZOLES | LANXESS DEUTSCHLAND GMBH (DE) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306397-A1 | Method for the production of substituted azoles | CYP11B1, CYP11B2, CYP4F11 | HRH3 926/4885ALDH1A1 389/4885GAA 1410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.